Fluoroquinolones

• 

  Subject Areas on Research

  • "Me-too" products--friend or foe? 
  • Antibiotic resistance: what is the impact of agricultural uses of antibiotics on children's health? 
  • Antibiotics exposure and risk of inflammatory bowel disease: a systematic review. 
  • Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis. 
  • Chlamydia pneumoniae and acute coronary syndrome. 
  • Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study. 
  • Community-Acquired Pneumonia in Adults: Diagnosis and Management. 
  • Cytotoxic clinical isolates of Pseudomonas aeruginosa identified during the Steroids for Corneal Ulcers Trial show elevated resistance to fluoroquinolones. 
  • Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database. 
  • Effect of Multi Drug Resistance Protein 4 (MRP4) Inhibition on the Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Normal and Rats with LPS-Induced Inflammation. 
  • Efficacy of Fluoroquinolone/Probiotic Combination Therapy for Recurrent Urinary Tract Infection in Children: A Retrospective Analysis. 
  • Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. 
  • Emergence of fluoroquinolone resistance among Bacteroides species. 
  • Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India. 
  • Epithelial wound healing after cataract surgery comparing two different topical fluoroquinolones. 
  • Fluoroquinolone prophylaxis reduces febrile neutropenia, bloodstream infections from mucosal translocations, and intensive care admissions in high risk hematological patients, a single center experience. 
  • Fluoroquinolone-based versus β-lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials. 
  • Genomic Analysis of Multidrug-Resistant Escherichia coli from North Carolina Community Hospitals: Ongoing Circulation of CTX-M-Producing ST131-H30Rx and ST131-H30R1 Strains. 
  • Glucose homeostasis abnormalities associated with use of gatifloxacin. 
  • History of antibiotics: from fluoroquinolones to daptomycin (Part 2). 
  • Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals. 
  • In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. 
  • In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. 
  • Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628. 
  • Methicillin-resistant Staphylococcus aureus (MRSA) pediatric tympanostomy tube otorrhea. 
  • Moxifloxacin-induced torsades de pointes. 
  • Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation. 
  • Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects. 
  • Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. 
  • Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis. 
  • Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections. 
  • Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy. 
  • Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. 
  • Provider and patient drivers of ototopical antibiotic prescription variability. 
  • Quinolones for community-acquired pneumonia. 
  • Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. 
  • Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. 
  • Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment. 
  • Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation. 
  • Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. 
  • Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. 
  • The Use of Systemic and Topical Fluoroquinolones. 
  • The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis? 
  • Torsades de pointes associated with fluoroquinolones. 
  • [Chiral separation of enantiomers of pazufloxacin by capillary electrophoresis].